The advantage of both CDI and CSA is to operate with preserved profiles of original tau conformers extracted from human AD brain tissue with minimal undesirable artificial modifications since these assays are independent of the absolute concentrations of misfolded tau protein and does not require in vitro amplification step or additional purification of PTA-extracts [35, 49]. This evidence concerns the gene MAPT and Alzheimer disease.